Back to top
more

Abeona Therapeutics Inc. (ABEO)

(Real Time Quote from BATS)

$20.90 USD

20.90
1,228,199

+0.90 (4.49%)

Updated Apr 20, 2018 03:58 PM ET

Add to portfolio

4-Sell       4  

F Value | F Growth | F Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1 Strong Buy 25.71%
2 Buy 18.12%
3 Hold 9.91%
4 Sell 5.49%
5 Strong Sell 2.29%
S&P 500 9.79%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Balance Sheet

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Research for ABEO

 

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

Fiscal Year End for Abeona Therapeutics Inc. falls in the month of December.

All items in Millions except Per Share data.

12/31/2017 12/31/2016 12/31/2015 12/31/2014 12/31/2013
Assets          
Cash & Equivalents 138 69 40 12 0
Receivables 0 0 0 0 0
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 3 0 0 0 0
Total Current Assets 141 69 41 12 1
Net Property & Equipment 1 1 0 0 0
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 36 41 39 5 0
Deposits & Other Assets 0 0 0 0 0
Total Assets 179 111 80 17 1
Liabilities & Shareholders Equity 12/31/2017 12/31/2016 12/31/2015 12/31/2014 12/31/2013
Notes Payable 0 1 1 0 0
Accounts Payable 2 4 1 2 1
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 1
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 3 4 0 1 7
Total Current Liabilities 6 8 1 3 9
Mortgages 0 0 0 0 0
Deferred Taxes/Income 3 4 4 5 5
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 7 4 1
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 9 12 12 12 15
Shareholders Equity 12/31/2017 12/31/2016 12/31/2015 12/31/2014 12/31/2013
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 529 431 378 301 251
Retained Earnings -360 -332 -311 -296 -266
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 170 99 68 5 -15
Total Liabilities & Shareholder's Equity 179 111 80 17 1
Total Common Equity 170 99 68 5 -15
Shares Outstanding 46.70 39.90 32.70 20.60 0.50
Book Value Per Share 3.64 2.48 2.07 0.23 -29.56

Fiscal Year End for Abeona Therapeutics Inc. falls in the month of December.

All items in Millions except Per Share data.

3/31/2018 12/31/2017 9/30/2017 6/30/2017 3/31/2017
Assets          
Cash & Equivalents NA 138 57 58 63
Receivables NA 0 0 0 0
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 3 2 1 0
Total Current Assets NA 141 58 59 64
Net Property & Equipment NA 1 1 1 1
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 36 37 37 41
Deposits & Other Assets NA 0 0 0 0
Total Assets NA 179 96 97 105
Liabilities & Shareholders Equity 3/31/2018 12/31/2017 9/30/2017 6/30/2017 3/31/2017
Notes Payable NA 0 0 0 1
Accounts Payable NA 2 2 4 1
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 3 1 1 4
Total Current Liabilities NA 6 3 4 6
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 3 3 3 4
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 0 0 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 9 6 8 10
Shareholders Equity 3/31/2018 12/31/2017 9/30/2017 6/30/2017 3/31/2017
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 529 441 435 433
Retained Earnings NA -360 -351 -346 -338
Other Equity NA 0 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 170 90 89 96
Total Liabilities & Shareholder's Equity NA 179 96 97 105
Total Common Equity 0 170 90 89 96
Shares Outstanding 47.20 46.70 46.00 40.20 40.20
Book Value Per Share 0.00 3.64 1.95 2.22 2.38